Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Diabetic Group | Elderly patients with type 2 diabetes mellitus. Participants will be evaluated for the presence or absence of sarcopenia using muscle ultrasound and clinical criteria. |
| |
| Non-Diabetic Group | Elderly patients without diabetes mellitus. Participants will also be assessed for sarcopenia using muscle ultrasound and standard diagnostic criteria. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| muscle ultrasound | Diagnostic Test | Bedside muscle ultrasound to measure muscle thickness, cross-sectional area and echogenicity |
|
| Measure | Description | Time Frame |
|---|---|---|
| Prevalence of sarcopenia assessed by muscle ultrasound in elderly diabetic | Sarcopenia will be evaluated using muscle ultrasound to measure muscle thickness and echo intensity of the quadriceps muscle. The results will be interpreted according to EWGSOP2 diagnostic criteria, which combine muscle mass and muscle strength parameters | Within 6 months from the start of recruitment. |
| Assessment of muscle strength using handgrip dynamometry | Handgrip strength will be measured using a handheld dynamometer, and the average of three attempts for the dominant hand will be recorded. | Within 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Quality of life score using the SarQoL questionnaire. | Quality of life related to sarcopenia will be evaluated using the validated SarQoL questionnaire. | Within 6 months. |
Not provided
Inclusion criteria:
The study will included all patient ,age ≥ 60 years,diagnosed with type 2 diabetes mellitus at least 5 years duraation according to ADA guideline referance(8) (diabetes can be made if a patient's A1C is 6.5% or higher, their FPG is 126 mg/dL or higher, or their 2-hour plasma glucose during an OGTT is 200 mg/dL or higher. A random plasma glucose of 200 mg/dL or higher, in conjunction with classic symptoms of hyperglycemia, also indicates diabetes)
●Able to give informed consent
Exclusion criteria:
Not provided
Not provided
Not provided
Inclusion criteria:
The study will included all patient ,age ≥ 60 years,diagnosed with type 2 diabetes mellitus at least 5 years duraation according to ADA guideline referance(8) (diabetes can be made if a patient's A1C is 6.5% or higher, their FPG is 126 mg/dL or higher, or their 2-hour plasma glucose during an OGTT is 200 mg/dL or higher. A random plasma glucose of 200 mg/dL or higher, in conjunction with classic symptoms of hyperglycemia, also indicates diabetes)
●Able to give informed consent
Exclusion criteria:
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| eman alaa eldean, master degree | Contact | 2+01098614329 | emanalaa359@gmail.com |
Not provided
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34904651 | Result | Feng L, Gao Q, Hu K, Wu M, Wang Z, Chen F, Mei F, Zhao L, Ma B. Prevalence and Risk Factors of Sarcopenia in Patients With Diabetes: A Meta-analysis. J Clin Endocrinol Metab. 2022 Apr 19;107(5):1470-1483. doi: 10.1210/clinem/dgab884. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D055948 | Sarcopenia |
| ID | Term |
|---|---|
| D009133 | Muscular Atrophy |
| D020879 | Neuromuscular Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| D001284 | Atrophy |
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012816 | Signs and Symptoms |